Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Adv Mater. 2021 Oct 11;33(49):e2103505. doi: 10.1002/adma.202103505

Figure 5.

Figure 5.

Immune recruitment and activation in vivo. a-h) Expression of maturation markers CD40 (a,b), CD80 (c,d), CD86 (e,f), and MHC-II (g,h) on CD11c+F4/80− dendritic cells within the CD45+ leukocyte population in tumors 1 day after intratumoral injection of Motor-OMV or control samples (n = 4, mean + SD). i,j) Percentage of infiltrating CD4+ (i) and CD8+ (j) T cells in tumors 4 days after Motor-OMV or control samples were administered intratumorally (n = 4, mean + SD). k-m) Levels of TNF-α (k), IL-6 (l), and IL-1β (m) in tumors 1 day after intratumoral treatment with Motor-OMV or control samples (n = 4, mean + SD). n-p) Levels of IL-2 (n), IL-12p40 (o), and IFN-γ (p) in tumors 4 days after Motor-OMV or control samples were injected intratumorally (n = 4, mean + SD). *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 (compared to Motor-OMV); #p < 0.05 and ##p < 0.01 (compared to static MP-OMV); one-way ANOVA.